TSX:ONC 1.70 CAD +0.00 +0% Volume: 10,801 April 23, 2014
NASDAQ:ONCY 1.54 USD +0.00 +0% Volume: 118,013 April 23, 2014

A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

Latest News

April 14, 2014 Oncolytics Biotech Inc. Collaborators Present Preclinical Research on Liver Cancer at UK Oncolytic Virus Conference
April 14, 2014 Oncolytics Biotech Inc. Collaborators Present Head and Neck Cancer Biomarker Preclinical Research at UK Oncolytic Virus Conference
April 11, 2014 Oncolytics Biotech Inc. Collaborators Present Translational Brain Cancer Clinical Data and Immunomodulatory Preclinical Research at UK Oncolytic Virus Conference
Sign up to receive e-mail updates *